GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Shiller PE Ratio

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCryst Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for BioCryst Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Shiller PE Ratio Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCryst Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCryst Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Shiller PE Ratio falls into.



BioCryst Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioCryst Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, BioCryst Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.31/129.4194*129.4194
=-0.310

Current CPI (Dec. 2023) = 129.4194.

BioCryst Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.170 99.695 -0.221
201406 -0.230 100.560 -0.296
201409 -0.120 100.428 -0.155
201412 -0.160 99.070 -0.209
201503 -0.210 99.621 -0.273
201506 0.060 100.684 0.077
201509 -0.200 100.392 -0.258
201512 -0.250 99.792 -0.324
201603 -0.310 100.470 -0.399
201606 -0.220 101.688 -0.280
201609 -0.160 101.861 -0.203
201612 -0.060 101.863 -0.076
201703 -0.190 102.862 -0.239
201706 -0.210 103.349 -0.263
201709 -0.180 104.136 -0.224
201712 -0.200 104.011 -0.249
201803 -0.260 105.290 -0.320
201806 -0.190 106.317 -0.231
201809 -0.280 106.507 -0.340
201812 -0.250 105.998 -0.305
201903 -0.280 107.251 -0.338
201906 -0.340 108.070 -0.407
201909 -0.340 108.329 -0.406
201912 -0.020 108.420 -0.024
202003 -0.240 108.902 -0.285
202006 -0.240 108.767 -0.286
202009 -0.260 109.815 -0.306
202012 -0.340 109.897 -0.400
202103 -0.360 111.754 -0.417
202106 -0.240 114.631 -0.271
202109 -0.330 115.734 -0.369
202112 -0.100 117.630 -0.110
202203 -0.400 121.301 -0.427
202206 -0.320 125.017 -0.331
202209 -0.230 125.227 -0.238
202212 -0.380 125.222 -0.393
202303 -0.280 127.348 -0.285
202306 -0.400 128.729 -0.402
202309 -0.190 129.860 -0.189
202312 -0.310 129.419 -0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCryst Pharmaceuticals  (NAS:BCRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BioCryst Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie director C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan officer: SR VP - CMO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703